A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 x2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects.

Trial Profile

A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 x2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2013

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy; Migraine; Multiple sclerosis; Neuropathic pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 19 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top